trending Market Intelligence /marketintelligence/en/news-insights/trending/ZUtQ34fNmBaTSmWvA9cICQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Report: Johnson & Johnson might break up Actelion in acquisition

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Report: Johnson & Johnson might break up Actelion in acquisition

Johnson & Johnson is in talks to break up Actelion Ltd. in its proposed acquisition, Reuters reported Dec. 29, citing "people familiar with the matter."

The deal would reportedly involve the separation of the Swiss biotechnology company's commercialized portfolio from its research and development assets, which would be placed in a new publicly traded company.

Reuters reported that Johnson & Johnson could offer Actelion around $260 per share in the deal, compared to its previously rejected offer that valued Actelion at about $26 billion.

The ownership and management structure for the new company is still being hashed out in the discussions, according to the anonymous sources.

A deal could reportedly be finalized by late January 2017.

The companies recently re-entered negotiations after the previous talks for a deal fell apart. French drugmaker Sanofi is also in advanced talks to acquire Actelion.